Article
Non-BRAF targeted therapies for melanoma: protein kinase inhibitors in Phase II clinical trials.
Expert opinion on investigational drugs - 1 Apr 2014
Bhatia Shilpa, Emdad Luni, Das Swadesh K, Hamed Hossein, Dent Paul, Sarkar Devanand, Fisher Paul B
Abstract excerpt
INTRODUCTION: Melanoma is one of the most aggressive forms of cutaneous malignancies displaying a substantial mortality rate among the various forms of skin cancers. The management of patients with advanced melanoma poses a significant challenge considering that the disease is refractory to most conventional therapies. AREAS COVERED: This review highlights some of the genes and signaling molecules that are...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.